Safety of Therapeutic Step-down in Neuromyelitis Optica
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Sponsor
- Enrollment
- 947
- Locations
- 1
- Primary Endpoint
- Retrospective evaluation of the risk of rebound during therapeutic escalations in neuromyelitis optica (NMO)
Study Overview
Brief Summary
Neuromyelitis Optica (NMO) is a neuroinflammatory disease related to multiple sclerosis (MS). It affects young subjects and causes a lot of handicap without treatment. Thus, aggressive treatments are frequently introduced early in the life of patients and maintained over the long term. A long duration of treatment exposes to iatrogenism. Therapeutic de-escalation trials in MS or other autoimmune diseases show rebound phenomena. In the NMO, there are no published data on the tolerance of desescalations to guide such strategies.
Study Design
- Study Type
- Observational
- Observational Model
- Case Only
- Time Perspective
- Retrospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- Not provided
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
Retrospective evaluation of the risk of rebound during therapeutic escalations in neuromyelitis optica (NMO)
Time Frame: Files analysed retrospectively from January 01, 2000 to December 31, 2020 will be examined]
Secondary Outcomes
No secondary outcomes reported